Literature DB >> 22385772

Cytomegalovirus infection in early childhood may be protective against glioblastoma multiforme, while later infection is a risk factor.

Steven Lehrer1.   

Abstract

Glioblastoma multiforme is the most common and most aggressive type of primary brain tumor, accounting for 52% of all primary brain tumor cases and 20% of all intracranial tumors. Recently, evidence for a viral cause has been postulated, possibly cytomegalovirus (CMV). In one report, 80% of patients with newly diagnosed glioblastoma multiforme had detectable cytomegalovirus DNA in their peripheral blood, while sero-positive normal donors and other surgical patients did not exhibit detectable virus. However, another study reported that five glioblastoma patients showed no circulating CMV detected either with RT-PCR or blood culture. But CMV could still be a factor in the genesis of glioblastoma multiforme, if age at infection is taken into account, since the incidence of both glioblastoma multiforme and CMV infection are inversely related to socioeconomic status. CMV infection in early childhood, more common in lower socioeconomic groups, may be protective against glioblastoma multiforme, whereas CMV infection in later childhood or adulthood may be a risk factor for glioblastoma. If so, glioblastoma multiforme occurrence would resemble paralytic polio, where low socioeconomic status, poor hygiene and early infection are protective.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22385772     DOI: 10.1016/j.mehy.2012.02.003

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  7 in total

1.  No circulating human cytomegalovirus in 14 cases of glioblastoma.

Authors:  Steven Lehrer; Sheryl Green; Kenneth E Rosenzweig; Angela Rendo
Journal:  Neuro Oncol       Date:  2014-12-01       Impact factor: 12.300

Review 2.  Insights into molecular therapy of glioma: current challenges and next generation blueprint.

Authors:  Y Rajesh; Ipsita Pal; Payel Banik; Sandipan Chakraborty; Sachin A Borkar; Goutam Dey; Ahona Mukherjee; Mahitosh Mandal
Journal:  Acta Pharmacol Sin       Date:  2017-03-20       Impact factor: 6.150

3.  Brain tumors incidences and a retrospective clinical analysis from a tertiary hospital in India.

Authors:  Ravindra Pramod Deshpande; Deepak Babu; Manas Panigrahi; Y B V K Chandra Sekhar; Phanithi Prakash Babu
Journal:  J Neurooncol       Date:  2016-06-16       Impact factor: 4.130

Review 4.  Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science.

Authors:  Fred H Hochberg; Nadia A Atai; David Gonda; Michael S Hughes; Brolin Mawejje; Leonora Balaj; Robert S Carter
Journal:  Expert Rev Mol Diagn       Date:  2014-05       Impact factor: 5.225

Review 5.  Epstein-Barr Virus in Gliomas: Cause, Association, or Artifact?

Authors:  Saghir Akhtar; Semir Vranic; Farhan Sachal Cyprian; Ala-Eddin Al Moustafa
Journal:  Front Oncol       Date:  2018-04-20       Impact factor: 6.244

6.  Novel management of glioma by molecular therapies, a review article.

Authors:  Amin Alinezhad; Fatemeh Jafari
Journal:  Eur J Transl Myol       Date:  2019-08-21

7.  Association between health insurance status and malignant glioma.

Authors:  Igor Fischer; Hendrik-Jan Mijderwijk; Ulf D Kahlert; Marion Rapp; Michael Sabel; Daniel Hänggi; Hans-Jakob Steiger; Marie-Therese Forster; Marcel A Kamp
Journal:  Neurooncol Pract       Date:  2020-06-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.